Hereditary Hemorrhagic Telangiectasia
41
4
7
26
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
2.4%
1 terminated out of 41 trials
96.3%
+9.8% vs benchmark
12%
5 trials in Phase 3/4
15%
4 of 26 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 26 completed trials
Clinical Trials (41)
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Ultra-low-dose Chest CT for HHT
CHORUS - Comprehensive HHT Outcomes Registry of the United States (Formerly OUR HHT Registry)
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
Stress-Echography in Hereditary Haemorrhagic Telangiectasia Patient With Hepatic Involvement
Cardiac Evaluation in Hereditary Hemorrhagic Telangiectasia
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia
Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)
Quality of Life in Patients With Hemorrhagic Telangiectasia
Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia
Sirolimus for Nosebleeds in HHT
Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs
Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Counseling Intervention in Hereditary Hemorrhagic Telangiectasia in the COVID Era.
Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia